Omar Ishrak - Medtronic PLC Chairman of the Board, Chief Executive Officer

MDT Stock  USD 86.92  3.22  3.85%   

Chairman

Mr. Omar Syed Ishrak, Ph.D., serves as Chairman of the Board, Chief Executive Officer of the Company. He was Chairman and Chief Executive Officer of the Company since January 2015 and of Medtronic, Inc. since June 2011. Prior to that, Mr. Ishrak served as President and Chief Executive Officer of GE Healthcare Systems, a division of GE Healthcare, from 2009 to 2011. Prior to that, Mr. Ishrak was President and Chief Executive Officer of GE Healthcare Clinical Systems from 2005 to 2008 and President and Chief Executive Officer of GE Healthcare Ultrasound and BMD from 1995 to 2004. since 2020.
Age 63
Tenure 4 years
Address 20 On Hatch, Dublin, Ireland, 2
Phone353 1 438 1700
Webhttps://www.medtronic.com
Ishrak was Chairman and Chief Executive Officer of Medtronic since 2011. Prior to joining Medtronic, Mr. Ishrak served as President and Chief Executive Officer of GE Healthcare Systems, a comprehensive provider of medical imaging and diagnostic technology and a division of GE Healthcare, from 2009 to 2011. Before that, Mr. Ishrak was President and Chief Executive Officer of GE Healthcare Clinical Systems from 2005 to 2008 and President and Chief Executive Officer of GE Healthcare Ultrasound and BMD from 1995 to 2004.

Medtronic PLC Management Efficiency

The company has Return on Asset of 0.0423 % which means that on every $100 spent on assets, it made $0.0423 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0817 %, implying that it generated $0.0817 on every 100 dollars invested. Medtronic PLC's management efficiency ratios could be used to measure how well Medtronic PLC manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to drop to 0.05 in 2024. Return On Assets is likely to drop to 0.04 in 2024. Total Current Liabilities is likely to gain to about 10.9 B in 2024. Liabilities And Stockholders Equity is likely to gain to about 109.8 B in 2024
The company has 24.36 B in debt with debt to equity (D/E) ratio of 0.51, which is OK given its current industry classification. Medtronic PLC has a current ratio of 1.72, which is typical for the industry and considered as normal. Debt can assist Medtronic PLC until it has trouble settling it off, either with new capital or with free cash flow. So, Medtronic PLC's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Medtronic PLC sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Medtronic to invest in growth at high rates of return. When we think about Medtronic PLC's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 5 records

CHAIRMAN Age

David KingLaboratory
61
Nissim DarvishMedigus Ltd ADR
N/A
Cesar AlvarezMednax Inc
71
Adam SchechterLaboratory
59
Isaiah HarrisCigna Corp
68
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The company was founded in 1949 and is headquartered in Dublin, Ireland. Medtronic operates under Medical Devices classification in the United States and is traded on New York Stock Exchange. It employs 95000 people. Medtronic PLC (MDT) is traded on New York Stock Exchange in USA. It is located in 20 On Hatch, Dublin, Ireland, 2 and employs 95,000 people. Medtronic PLC is listed under Health Care Equipment & Supplies category by Fama And French industry classification.

Management Performance

Medtronic PLC Leadership Team

Elected by the shareholders, the Medtronic PLC's board of directors comprises two types of representatives: Medtronic PLC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Medtronic. The board's role is to monitor Medtronic PLC's management team and ensure that shareholders' interests are well served. Medtronic PLC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Medtronic PLC's outside directors are responsible for providing unbiased perspectives on the board's policies.
Brett Wall, Executive Vice President and President Restorative Therapies Group
Jennifer Kirk, Chief Accounting Officer, Global Controller
Bradley Lerman, Senior Vice President General Counsel, Corporate secretary
Scott Donnelly, Lead Independent Director
Kenneth Washington, Senior Officer
Richard Anderson, Lead Independent Director
Ryan Weispfenning, Vice President - Investor Relations
Mark Ploof, Senior Services
Sean Lennon, Chief Officer
Hooman Hakami, Executive Vice President and Group President of the Medtronic Diabetes Group
Elizabeth Nabel, Independent Director
Richard Kuntz, Senior Vice President and Chief Scientific, Clinical and Regulatory Officer
James Lenehan, Independent Director
John Liddicoat, Executive Vice President and President Americas Region
Shirley Jackson, Independent Director
Robert White, Executive Vice President and President of Medtronic’s Minimally Invasive Therapies Group
Preetha Reddy, Independent Director
Kevin Lofton, Independent Director
Craig Arnold, Independent Director
Robert Pozen, Independent Director
Kendall Powell, Lead Independent Director
Bryan Hanson, Executive VP and Group President of Minimally Invasive Therapies Group
Sally Saba, Chief Inclusion and Diversity Officer
Denise OLeary, Independent Director
Omar Ishrak, Chairman of the Board, Chief Executive Officer
Brad Lerman, Senior Vice President General Counsel, Corporate secretary
Ivan Fong, General VP
Sean Salmon, Executive Vice President and President, Diabetes Operating Unit, President, Cardiovascular Portfolio
Gary Ellis, CFO and Executive VP
Carol Surface, Chief Human Resource Officer, Senior Vice President
Karen Parkhill, Chief Financial Officer, Executive Vice President
Geoff Martha, Executive Vice President and President - Restorative Therapies Group
Michael Leavitt, Independent Director
Geoffrey Martha, Executive Vice President and President - Restorative Therapies Group
Randall Hogan, Independent Director
Andrea Goldsmith, Independent Director
Robert Hoedt, Executive Vice President and President - EMEA Region
MSc MD, Medical Scientific
Michael Coyle, Executive Vice President, Group President - Cardiac and Vascular Group

Medtronic Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Medtronic PLC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Medtronic PLC is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Medtronic Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Medtronic Plc Stock. Highlighted below are key reports to facilitate an investment decision about Medtronic Plc Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Medtronic PLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.
For more information on how to buy Medtronic Stock please use our How to Invest in Medtronic PLC guide.
Note that the Medtronic PLC information on this page should be used as a complementary analysis to other Medtronic PLC's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Complementary Tools for Medtronic Stock analysis

When running Medtronic PLC's price analysis, check to measure Medtronic PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medtronic PLC is operating at the current time. Most of Medtronic PLC's value examination focuses on studying past and present price action to predict the probability of Medtronic PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medtronic PLC's price. Additionally, you may evaluate how the addition of Medtronic PLC to your portfolios can decrease your overall portfolio volatility.
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Bonds Directory
Find actively traded corporate debentures issued by US companies
Is Medtronic PLC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Medtronic PLC. If investors know Medtronic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Medtronic PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.078
Dividend Share
2.75
Earnings Share
3.15
Revenue Per Share
24.298
Quarterly Revenue Growth
0.047
The market value of Medtronic PLC is measured differently than its book value, which is the value of Medtronic that is recorded on the company's balance sheet. Investors also form their own opinion of Medtronic PLC's value that differs from its market value or its book value, called intrinsic value, which is Medtronic PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Medtronic PLC's market value can be influenced by many factors that don't directly affect Medtronic PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Medtronic PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if Medtronic PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Medtronic PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.